Hengrui Pharma to present 64 research studies at ESMO 2026

Hengrui Pharma has announced that 64 of its research findings have been accepted for presentation at the 2026 European Society for Medical Oncology (ESMO) congress. The selection includes three Proffered Paper presentations and three Rapid Oral presentations.

The research spans more than ten areas of oncology and supportive care. Over ten studies focus on HER2- and HER3-targeted therapies, reflecting the company’s efforts to advance its clinical pipeline. These presentations aim to provide data regarding the efficacy and safety profile of its drug candidates.

The ESMO congress serves as a primary venue for oncology research, attracting researchers and pharmaceutical companies to share data on new treatment modalities. Hengrui Pharma’s participation signals its ongoing investment in clinical development programs intended for international markets.

The company’s presence at the conference is expected to clarify its competitive position in the oncology sector as it continues to advance its therapeutic pipeline.